DBV Technologies (NASDAQ:DBVT) Given New $45.00 Price Target at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its price objective hoisted by stock analysts at Citizens Jmp from $21.00 to $45.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price target indicates a potential upside of 150.28% from the stock’s current price.

Several other research analysts also recently commented on DBVT. Cantor Fitzgerald raised shares of DBV Technologies to a “strong-buy” rating in a research note on Monday. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Guggenheim reissued a “buy” rating and issued a $51.00 price target (up from $35.00) on shares of DBV Technologies in a research note on Wednesday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective (up previously from $20.00) on shares of DBV Technologies in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.54.

DBV Technologies Trading Down 1.7%

Shares of DBV Technologies stock opened at $17.98 on Wednesday. The firm has a market capitalization of $722.08 million, a PE ratio of -3.48 and a beta of -1.10. DBV Technologies has a 12 month low of $2.74 and a 12 month high of $21.50. The business’s 50-day moving average price is $14.98 and its 200-day moving average price is $11.58.

Hedge Funds Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $9,659,000. Vivo Capital LLC bought a new position in shares of DBV Technologies during the second quarter valued at approximately $9,659,000. MPM Bioimpact LLC bought a new position in shares of DBV Technologies during the second quarter valued at approximately $9,649,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the second quarter worth $9,315,000. Finally, Millennium Management LLC boosted its holdings in DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after acquiring an additional 69,849 shares in the last quarter. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.